A Double-blind Comparison of Galantamine Hydrogen Bromide and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder: A Pilot Study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Galantamine hydrogen bromide (HBr) is a competitive and reversible inhibitor of acetylcholinesterase. Because of its cholinergic nicotinic mechanism of action, galantamine HBr was hypothesized to have therapeutic activity in the treatment of attention-deficit/hyperactivity disorder (ADHD). METHOD: We conducted a 12-week, double-blind, placebo-controlled, randomized clinical trial using daily doses of up to 24 mg/d of galantamine HBr in the treatment of adults who met full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD with childhood-onset and persistent adult symptoms. All analyses were intention to treat with the last observation carried forward for subjects who did not complete the full study schedule. RESULTS: The mean daily doses at week 12 were 19.8 +/- 6.4 mg for galantamine HBr and 21.8 +/- 4.6 mg for placebo (P = 0.3). There was no statistically or clinically significant greater reduction in ADHD symptoms in subjects treated with galantamine HBr relative to those receiving placebo (P = 0.5). Using last observation carried forward, 4 (22%) of 18 of patients receiving galantamine HBr were considered responders (much or very much improved on the Clinical Global Impression Improvement Scale and at least a 30% reduction on the ADHD Investigator Symptom Report Scale compared with 11% [2/18] on placebo; P = 0.4). CONCLUSION: These results do not support the clinical utility of galantamine HBr in the treatment of ADHD at the doses used in this pilot study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biederman, J., Monuteaux, M. C., Doyle, A. E., Seidman, L. J., Wilens, T. E., Ferrero, F., Morgan, C. L., & Faraone, S. V. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.5.757 · Cited by 881
Self-citationSpencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402
Self-citationSpencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., & Bearman, S. K. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.775 · Cited by 250
Self-citationWilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1931 · Cited by 230
Self-citation
Cited by
Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis
Mészáros, Á., Czobor, P., Bálint, S., Komlósi, S., Simon, V., & Bitter, I. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990198 · Cited by 138
“Pilot studies or studies that tested drugs that subsequently have been shown to lack efficacy in ADHD were not included in the current analysis (Biederman et al. 2006).”
BackgroundPotter, A. S., Schaubhut, G., & Shipman, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0208-9 · Cited by 64
Santosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
Ivanchak, N., Fletcher, K., & Jicha, G. A. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0305-8 · Cited by 54
“Borrowing a page from the MCI/dementia literature, several studies have examined the effects of acetylcholinesterase inhibitors in ADHD [83, 84, 88, 100].”
BackgroundGjerden, P., Bramness, J. G., Tvete, I. F., & Slørdal, L. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2281-8 · Cited by 48
Metadata
- Authors
- Biederman, J., Mick, E., Faraone, S., Hammerness, P., Surman, C., Harpold, T., Dougherty, M., Aleardi, M., & Spencer, T.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2006-04
- Volume
- 26
- Issue
- 2
- Pages
- 163-166
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2076526042
- Cited by
- 37
- References
- 4
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-blind Comparison of Galantamine Hydrogen Bromide and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder: A Pilot Study. https://app.cochat.ai/papers/10.1097/01.jcp.0000204139.20417.8a
- The paper
- Biederman, J., Mick, E., Faraone, S., Hammerness, P., Surman, C., Harpold, T., Dougherty, M., Aleardi, M., & Spencer, T. (2006). A Double-blind Comparison of Galantamine Hydrogen Bromide and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder: A Pilot Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000204139.20417.8a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.